Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140008/S028

ORBERA INTRAGASTRIC BALLOON

BOSTON SCIENTIFIC CORPORATION · Decision date Jan 5, 2026

FDA DECISIONP140008/S028

What did the FDA approve?

FDA records P140008/S028 as a supplement to PMA P140008, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jan 5, 2026.

FDA approval order statement

a manufacturing site change to replace the Apollo Endosurgery Coyol, Costa Rica facility with the Boston Scientific Coyol, Costa Rica facility for the Orbera Intragastric Balloon, following acquisition of Apollo Endosurgery by Boston Scientific
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Gastroenterology, Urology
Decision date
Jan 5, 2026
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P140008/S028
Regulatory pathway
PMA supplement
Product code
LTI
Decision code
APPR
Decision date
Jan 5, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY.

Product code
LTI
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P140008/S028 received

    Application receipt date recorded by FDA.

  2. P140008/S028 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P140008. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code LTI

Product / regulatory recordCompanyPathwayDecision dateSource
Allurion Technologies, Inc.PMA supplementSep 23, 2026FDA
Allurion Technologies, Inc.PMA supplementSep 9, 2026FDA
Allurion Technologies, Inc.PMA approvalFeb 20, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
100 Boston Scientific Way, Marlboro, MA, 01752

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records